Carbometrics

Carbometrics Ltd. is a biotechnology and supramolecular chemistry company based in Bristol, United Kingdom.

Founded in 2018, it emerged from the acquisition of Ziylo Ltd. by Novo Nordisk. The company operates from the Science Creates St Philips incubator and is supported by investors such as Parkwalk Advisors and Ada Ventures. Carbometrics focuses on developing advanced technologies for Continuous Glucose Monitoring (CGM) and smart insulin therapies. Its primary product, the i-CAM, is a Continuous Metabolic Monitor designed for cardiopulmonary bypass and organ perfusion circuits. The company also creates highly accurate glucose sensing platforms using proprietary Glucose Binding Molecules (GBMs). Additionally, Carbometrics offers research and development services, including glucose-sensing assays and support for drug discovery projects. The company collaborates with strategic partners, including Novo Nordisk, to advance its innovative solutions in diabetes management.